BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ribes S, Taberner F, Domenech A, Cabellos C, Tubau F, Liñares J, Viladrich PF, Gudiol F. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 2006;57:931-6. [DOI: 10.1093/jac/dkl047] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Chavanet P. [Presumptive bacterial meningitis in adults: initial antimicrobial therapy]. Med Mal Infect 2009;39:499-512. [PMID: 19428207 DOI: 10.1016/j.medmal.2009.02.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009;18:921-944. [PMID: 19548851 DOI: 10.1517/13543780902967624] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
3 Allen KD, Wang SC. Initial characterization of Fom3 from Streptomyces wedmorensis: The methyltransferase in fosfomycin biosynthesis. Arch Biochem Biophys 2014;543:67-73. [PMID: 24370735 DOI: 10.1016/j.abb.2013.12.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
4 Woodyer RD, Shao Z, Thomas PM, Kelleher NL, Blodgett JA, Metcalf WW, van der Donk WA, Zhao H. Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster. Chem Biol 2006;13:1171-82. [PMID: 17113999 DOI: 10.1016/j.chembiol.2006.09.007] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 5.3] [Reference Citation Analysis]
5 Woodyer RD, Li G, Zhao H, van der Donk WA. New insight into the mechanism of methyl transfer during the biosynthesis of fosfomycin. Chem Commun (Camb) 2007;:359-61. [PMID: 17220970 DOI: 10.1039/b614678c] [Cited by in Crossref: 96] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
6 Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 2015;70:3042-50. [PMID: 26209311 DOI: 10.1093/jac/dkv221] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
7 Sauermann R, Schwameis R, Fille M, Ligios ML, Zeitlinger M. Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemother 2009;64:821-3. [PMID: 19622535 DOI: 10.1093/jac/dkp261] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
8 Schwameis R, Fille M, Manafi M, Zeitlinger M, Sauermann R. Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid. Res Microbiol 2012;163:157-60. [PMID: 22210435 DOI: 10.1016/j.resmic.2011.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
9 Fransen F, Hermans K, Melchers MJB, Lagarde CCM, Meletiadis J, Mouton JW. Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2017;72:3374-81. [PMID: 29029067 DOI: 10.1093/jac/dkx328] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
10 Schweifer A, Hammerschmidt F. On the conversion of structural analogues of (S)-2-hydroxypropylphosphonic acid to epoxides by the final enzyme of fosfomycin biosynthesis in S. fradiae. Bioorganic & Medicinal Chemistry Letters 2008;18:3056-9. [DOI: 10.1016/j.bmcl.2007.12.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Darlow CA, da Costa RMA, Ellis S, Franceschi F, Sharland M, Piddock L, Das S, Hope W. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Paediatr Drugs 2021;23:465-84. [PMID: 34435316 DOI: 10.1007/s40272-021-00465-z] [Reference Citation Analysis]
12 Oliva A, Furustrand Tafin U, Maiolo EM, Jeddari S, Bétrisey B, Trampuz A. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrob Agents Chemother 2014;58:1284-93. [PMID: 24145537 DOI: 10.1128/AAC.02583-12] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
13 Zozaya DH, Gutiérrez OL, Ocampo CL, Sumano LH. Pharmacokinetics of a single bolus intravenous, intramuscular and subcutaneous dose of disodium fosfomycin in horses. J Vet Pharmacol Ther 2008;31:321-7. [PMID: 18638292 DOI: 10.1111/j.1365-2885.2008.00970.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
14 Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother 2013;57:1421-7. [PMID: 23295934 DOI: 10.1128/AAC.01718-12] [Cited by in Crossref: 76] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
15 Kussmann M, Baumann A, Hauer S, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. Eur J Clin Microbiol Infect Dis 2017;36:2237-42. [PMID: 28685187 DOI: 10.1007/s10096-017-3051-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Xie F, Chao Y, Xue Z, Yang X, Zhang G, Shi J, Qian S. Stereoselective epoxidation of cis-propenylphosphonic acid to fosfomycin by a newly isolated bacterium Bacillus simplex strain S101. J Ind Microbiol Biotechnol 2009;36:739-46. [DOI: 10.1007/s10295-009-0546-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Antonello RM, Principe L, Maraolo AE, Viaggi V, Pol R, Fabbiani M, Montagnani F, Lovecchio A, Luzzati R, Di Bella S. Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics (Basel) 2020;9:E500. [PMID: 32785114 DOI: 10.3390/antibiotics9080500] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
18 Cao Y, Peng Q, Li S, Deng Z, Gao J. The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic. RSC Adv 2019;9:42204-18. [DOI: 10.1039/c9ra08299a] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
19 Hashemian SMR, Farhadi Z, Farhadi T. Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag 2019;15:525-30. [PMID: 30988619 DOI: 10.2147/TCRM.S199119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
20 Stahl JP. [Treatment of community acquired bacterial meningitis, after microbiological identification]. Med Mal Infect 2009;39:513-20. [PMID: 19394177 DOI: 10.1016/j.medmal.2009.02.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 . Reactions Involving Oxygenases. Redox Biocatalysis. Hoboken: John Wiley & Sons, Inc.; 2012. pp. 180-302. [DOI: 10.1002/9781118409343.ch4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Mihailescu R, Furustrand Tafin U, Corvec S, Oliva A, Betrisey B, Borens O, Trampuz A. High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2014;58:2547-53. [PMID: 24550327 DOI: 10.1128/AAC.02420-12] [Cited by in Crossref: 68] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
23 Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009;34:506-15. [PMID: 19828298 DOI: 10.1016/j.ijantimicag.2009.08.013] [Cited by in Crossref: 115] [Cited by in F6Publishing: 117] [Article Influence: 8.8] [Reference Citation Analysis]
24 Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011;15:e732-9. [PMID: 21945848 DOI: 10.1016/j.ijid.2011.07.007] [Cited by in Crossref: 215] [Cited by in F6Publishing: 186] [Article Influence: 19.5] [Reference Citation Analysis]
25 Tang HJ, Chen CC, Cheng KC, Toh HS, Su BA, Chiang SR, Ko WC, Chuang YC. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J Antimicrob Chemother 2012;67:944-50. [PMID: 22258931 DOI: 10.1093/jac/dkr535] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
26 Chiavolini D, Pozzi G, Ricci S. Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev 2008;21:666-85. [PMID: 18854486 DOI: 10.1128/CMR.00012-08] [Cited by in Crossref: 79] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
27 Prutthiwanasan B, Suntornsuk L. Rapid analysis of alkylphosphonate drugs by capillary zone electrophoresis using indirect ultraviolet detection: Electrodriven Separations. J Sep Science 2010;33:228-34. [DOI: 10.1002/jssc.200900518] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]